Co-Authors
This is a "connection" page, showing publications co-authored by ERIK PHILIP SULMAN and MARTA PENAS-PRADO.
Connection Strength
0.338
-
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. Cancer. 2019 02 01; 125(3):424-433.
Score: 0.162
-
A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma. Neuro Oncol. 2021 08 02; 23(8):1337-1347.
Score: 0.049
-
Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab073.
Score: 0.049
-
Differences in patterns of care and outcomes between grade II and grade III molecularly defined 1p19q co-deleted gliomas. Clin Transl Radiat Oncol. 2019 Feb; 15:46-52.
Score: 0.041
-
An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Neuro Oncol. 2017 05 01; 19(5):669-677.
Score: 0.037